Intracerebral Hemorrhage in a Patient with Multiple Sclerosis Receiving Interferon Beta-1α

Interferon beta-1α (IFN β-1α) is one of the most widely used disease-modifying drugs, resulting in reduced annualized relapse rates and MRI activity in patients with multiple sclerosis (MS). Years of experience has indicated the relative safety of this class of medications in patients with MS. Despite its overall safety profile, an increasing number of reports have revealed serious adverse events in form of angiopathic complications in the preceding years. Herein, we present the case of a patient with chronic MS under treatment with IFN β-1α, presenting with intracerebral hemorrhage (ICH) without any other identifiable causes. The present report, along with various cases of bleeding in patients receiving IFN, indicates a possible association between IFN therapy and ICH.